Zytovision
ZytoVision is a German IVD manufacturer that designs FISH and CISH probe kits for cancer and infectious-disease diagnostics, sold globally to certified pathology laboratories through a distributor network across 80+ countries.
- Company typePrivate
- Founded2004
- HeadquartersBremerhaven, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zytovision does
ZytoVision GmbH, headquartered in Bremerhaven, Germany and founded in 2004 by Dr. Sven Hauke and Dr. Piere Marggraf-Rogalla, designs, manufactures and distributes in vitro diagnostic (IVD) reagents for molecular tumor and infectious-disease diagnostics based on in situ hybridization. The company operates from a single Bremerhaven headquarters (Fischkai 1) with a workforce of 11–50 employees and is privately held under the ZYTOMICS umbrella, owned by private-equity firm ArchiMed since the January 2021 acquisition of the Zyto Group of Cancer Diagnostics companies. Its current Managing Directors are Bastian Eirich and Claudia Zimmer.
Zytovision firmographics
Firmographics- Name
- Zytovision
- Legal name
- ZytoVision GmbH
- Website
- https://zytovision.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ZytoVision is a German IVD manufacturer that designs FISH and CISH probe kits for cancer and infectious-disease diagnostics, sold globally to certified pathology laboratories through a distributor network across 80+ countries.
- Ownership category
- akta.pro rank
Zytovision industry classification
Industry- Product category
- Molecular Diagnostics (In Vitro Diagnostics)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where Zytovision is headquartered
LocationHeadquarters
- HQ city
- Bremerhaven
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Zytovision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- IVD Diagnostic Products: Sale of in vitro diagnostic products including FISH probes (ZytoLight, FlexISH, ZytoMation), CISH products (ZytoDot 2C, ZytoFast PLUS), and VisionArray chip-based detection systems for tumor diagnostics and pathogen detection.
- Workshop and Training Services: FISH Expert Evaluation Workshops offered to customers and distributors for training on evaluation techniques.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Zytovision product offering
Product offeringCore offering
ZytoVision designs, develops, and manufactures in vitro diagnostic (IVD) products for tumor and infectious disease diagnostics based on in situ hybridization (FISH and CISH) and DNA microarray technologies. The portfolio includes direct-labeled and automated FISH probes, two-color and rapid CISH detection systems, and VisionArray microarray chips with dedicated software for HPV genotyping, Mycobacteria, and Fungi detection, sold exclusively to certified anatomic pathology and clinical laboratories through a global distributor network.
Product overview
Zytovision is a manufacturer of in vitro diagnostic products for tumor diagnosis based on in situ hybridization techniques (FISH and CISH). The product portfolio consists of six core product lines: (1) ZytoLight® — direct-labeled FISH probes for detecting genetic aberrations (translocations, deletions, amplifications, aneuploidies) in FFPE and cytology specimens; (2) F*lex*ISH® — flexible FISH probes with adaptable 1-day or 2-day hybridization protocols and DistinguISH™ dual-gene detection capability; (3) ZytoMation® — fully automated FISH probes for Leica BOND™ systems; (4) ZytoDot® 2C — two-color CISH for light microscopy detection of genomic alterations; (5) ZytoFast® PLUS — rapid CISH for pathogen virus detection (HPV, EBV, CMV) and lymphocyte clonality; and (6) VisionArray® — microarray-based DNA detection system with chips for HPV genotyping (41 types), Mycobacteria species, and pathogenic Fungi (30 genotypes), each with corresponding PreCise Master Mix reagents, a Detection Kit, and MultiScan/SingleScan analysis software. Supporting accessories include implementation kits, pretreatment reagents, wash buffers, DAPI/DuraTect™ counterstaining solutions, and autofluorescence quenching reagents. The product range covers solid tumor and hematology applications across multiple technique platforms (FISH, CISH, microarray).
Differentiator
Problem solved
Functional benefit
Brands
- ZYTOMICS: Unified brand name for ZytoVision GmbH, Zytomed Systems GmbH, 42 life sciences, and Diagomics following the June 2024 rebranding initiative.
Products and services
- ZytoLight FISH Probes Direct-labeled fluorescence in situ hybridization (FISH) probes for detecting genetic aberrations including translocations, deletions, amplifications, and chromosomal aneuploidies in FFPE tissue and cytology specimens. Uses proprietary fluorochrome technology that eliminates the need for fluorophore-coupled antibody detection. Designed for certified anatomic pathology laboratories performing cancer diagnostics.
- FlexISH FISH Probes
- ZytoMation Automated FISH Probes Fully automated FISH probes designed for Leica BOND-III, BOND-MAX, and BOND RXm systems to detect genetic aberrations such as translocations and amplifications in FFPE tissue sections. Features a fully automated 5-hour protocol with reduced hands-on time. For clinical pathology laboratories using Leica BOND automation.
- ZytoDot 2C CISH Products Two-color chromogenic in situ hybridization (CISH) products for simultaneous detection of two genomic targets using light microscopy. Differentiates aneuploidies from gene amplifications and detects deletions and translocations in FFPE tissue sections. For cancer diagnostics laboratories.
- ZytoFast PLUS CISH Products Chromogenic in situ hybridization (CISH) products for fast detection and discrimination of human pathogen viruses (HPV, EBV, CMV) and determination of lymphocyte clonality via Ig-\u03ba and Ig-\u03bb light chain RNA detection. Results achievable in 4 hours. For clinical pathology and infectious disease laboratories.
- VisionArray DNA Detection System Array-based DNA detection system using DNA/DNA hybridization on glass chips with a 1-hour protocol and automated evaluation via VisionArray Software. Targets include HPV genotypes, Mycobacteria species, and pathogenic Fungi. System comprises chips, PreCise Master Mix reagents, Detection Kit, and MultiScan/SingleScan software. For clinical laboratories performing pathogen genotyping.
Companies that use Zytovision
Customer profileSegments2 records
Ideal customer profiles2 records
Zytovision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature5 records
Zytovision partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and secondary.
- BMBF Research NetworkcoreCollaboration with BMBF (German Federal Ministry of Education and Research) research network for EDI-4-ALL project to establish methods for early detection of genetic predisposition to acute lymphoblastic leukemia in newborns.
- ZYTOMICS (Parent Brand)coreZytoVision GmbH, Zytomed Systems GmbH, 42 life sciences, and Diagomics have been combined under the brand-new name ZYTOMICS as of June 2024. ZytoVision is a ZYTOMICS company.
- Universitätsklinikum EssensecondaryFlexTrack project collaboration with Universitätsklinikum Essen to establish FISH for multiplexed cell tracking in tumor progression.
- Charité BerlinsecondaryALLFISHinFlow project cooperation with Charité Berlin for development of FISH-based flow cytometry applications.
- Leica BiosystemscoreZytoMation probes are specifically designed for use with Leica BOND systems (BOND-III, BOND-MAX, BOND RXm). The probes require Leica BOND FISH Kit and BOND Enzyme Pretreatment Kit for automated staining protocols. Note: ZytoVision is not affiliated or associated with Leica Biosystems.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Zytovision competitors and assessment
Company assessmentDirect peers
- Empire Genomics: US-based FISH probe manufacturer specializing in customized and catalog FISH probes for cancer and constitutional cytogenetics research and diagnostics. Comparable as a FISH-only reagent specialist targeting academic and clinical cytogenetics labs.
- MetaSystems: German manufacturer of automated FISH scanning systems and FISH probes for cytogenetics, hematology, and solid tumor diagnostics. Directly comparable as a mid-sized European FISH reagent and instrument vendor serving the same anatomic pathology and cytogenetic laboratory customers.
Broad incumbents
- Agilent Technologies (Dako): Agilent's Dako pathology business sells FISH probes for HER2, ALK, and other oncology targets alongside IHC reagents and Omnis automation. A broad incumbent with overlapping FISH content and integrated companion-diagnostic capability for pharma partners.
- Roche Diagnostics (Ventana): Roche's diagnostics arm sells FISH probes alongside its Ventana IHC and BenchMark automation platforms, as well as the Foundation Medicine NGS franchise. A broad incumbent that competes in companion diagnostics and integrated pathology workflows where ZytoVision's FISH products are used.
- Hologic: Diagnostics company with the ThinPrep cytology platform and molecular diagnostics franchise (Panther, Aptima) addressing cervical cancer screening and infectious disease - adjacent applications that overlap with VisionArray HPV and ZytoVision's cytology FISH workflow.
- Abbott Molecular (Vysis): Abbott's molecular diagnostics division (including the acquired Vysis FISH probe business and CytoCell) sells FDA-cleared FISH probe panels for ALK, ROS1, HER2, and other oncology biomarkers. A broad incumbent offering overlapping FISH content plus larger molecular diagnostics menu, including PCR and NGS.
Others
- Leica Biosystems: Histopathology and FISH workflow solutions provider, owner of the BOND automated staining platform with which ZytoMation probes integrate. Strategic partner (ZytoVision notes it is not affiliated with Leica) but also a competitor through Kreatech FISH reagents and broader anatomic pathology offerings.
- Bio-Techne: Life science tools and diagnostics company offering proteins, antibodies, and ExoDx molecular diagnostics, with a portfolio spanning research reagents and clinical diagnostics adjacent to ZytoVision's reagent-focused business model.
Emerging players
- Oxford Gene Technology (OGT): UK-based molecular diagnostics company offering FISH probes and NGS-based cytogenetics products for cancer and constitutional genetic disorders. Comparable as a niche molecular cytogenetics specialist with overlapping oncology FISH menu and growing NGS adjacency.
Regional players
- Vitro Master Diagnóstica: Spanish IVD manufacturer distributing FISH and CISH probes for cytogenetics and oncology across Latin America and Southern Europe. Comparable as a regional FISH probe specialist with overlapping product categories but distinct geographic focus from ZytoVision's wider footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Zytovision social profiles
Digital presenceZytovision compliance and trust
Trust signalCompliance4 records
Zytovision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zytovision leadership team
Management profileNumber of profiles
Profiles3 records
Zytovision funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zytovision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zytovision
What does Zytovision do?
ZytoVision designs, develops, and manufactures in vitro diagnostic (IVD) products for tumor and infectious disease diagnostics based on in situ hybridization (FISH and CISH) and DNA microarray technologies. The portfolio includes direct-labeled and automated FISH probes, two-color and rapid CISH detection systems, and VisionArray microarray chips with dedicated software for HPV genotyping, Mycobacteria, and Fungi detection, sold exclusively to certified anatomic pathology and clinical laboratories through a global distributor network.
Is Zytovision a public or private company?
Zytovision is a private company. It is classified as private equity controlled and is currently operating.
When was Zytovision founded?
Zytovision was founded in 2004. It employs 11 to 50 people.
Where is Zytovision based?
Zytovision is headquartered in Bremerhaven, Germany, in the Europe region.
How does Zytovision make money?
Two revenue lines are on record. IVD Diagnostic Products are the primary driver. The others are workshop and Training Services.
Who are Zytovision's main competitors?
Direct peers on record are Empire Genomics and MetaSystems. Broad incumbents are Agilent Technologies (Dako), Roche Diagnostics (Ventana), Hologic and Abbott Molecular (Vysis). Others are Leica Biosystems and Bio-Techne. Oxford Gene Technology (OGT) is listed as an emerging player. Vitro Master Diagnóstica is listed as a regional player.
Does Zytovision have an API?
No public API is recorded for Zytovision.
What industry is Zytovision in?
Zytovision's product category is Molecular Diagnostics (In Vitro Diagnostics). Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics). Its NAICS code is 325413 and its SIC code is 2835.